Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Dror Michaelson

Showing results (21-30 of 121) with videos related to

Pageof 13
Sort By:
Cancer|June 29, 2006
Randomized phase II study of atrasentan alone or in combination with zoledronic acid in men with metastatic prostate cancerM Dror Michaelson, Donald S Kaufman, Philip Kantoff, et al.
Clinical Genitourinary Cancer|September 18, 2016
Heterogeneity of Patients With Intermediate-Prognosis Metastatic Renal Cell Carcinoma Treated With SunitinibAvishay Sella, M Dror Michaelson, Ewa Matczak, et al.
Plos One|August 30, 2019
Treatment sequences for advanced renal cell carcinoma: A health economic assessmentBaris Deniz, Apoorva Ambavane, Shuo Yang, et al.
The New England Journal of Medicine|September 15, 2006
Case records of the Massachusetts General Hospital. Case 28-2006. A 59-year-old man with masses in both kidneysW Scott McDougal, Nina E Tolkoff-Rubin, M Dror Michaelson, et al.
The Journal of Urology|April 20, 2010
Application of a fracture risk algorithm to men treated with androgen deprivation therapy for prostate cancerPhilip J Saylor, Donald S Kaufman, M Dror Michaelson, et al.
Academic Radiology|March 16, 2005
Arterial spin labeling blood flow magnetic resonance imaging for the characterization of metastatic renal cell carcinoma(1)Cedric De Bazelaire, Neil M Rofsky, Guillaume Duhamel, et al.
The New England Journal of Medicine|May 30, 2008
Case records of the Massachusetts General Hospital. Case 17-2008. A 63-year-old man with metastatic renal-cell carcinomaM Dror Michaelson, Othon Iliopoulos, David F McDermott, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|September 18, 2012
Multitargeted tyrosine kinase inhibition produces discordant changes between 99mTc-MDP bone scans and other disease biomarkers: analysis of a phase II study of sunitinib for metastatic castration-resistant prostate cancerPhilip J Saylor, Umar Mahmood, Anchisa Kunawudhi, et al.
Plos One|August 31, 2018
Application of dynamic modeling for survival estimation in advanced renal cell carcinomaBaris Deniz, Arman Altincatal, Apoorva Ambavane, et al.
CA: a Cancer Journal for Clinicians|May 27, 2008
Management of complications of prostate cancer treatmentM Dror Michaelson, Shane E Cotter, Patricio C Gargollo, et al.
Pageof 13

Showing results (21-30 of 121) with videos related to

Sort By:
Pageof 13
Cancer|June 29, 2006
Randomized phase II study of atrasentan alone or in combination with zoledronic acid in men with metastatic prostate cancerM Dror Michaelson, Donald S Kaufman, Philip Kantoff, et al.
Clinical Genitourinary Cancer|September 18, 2016
Heterogeneity of Patients With Intermediate-Prognosis Metastatic Renal Cell Carcinoma Treated With SunitinibAvishay Sella, M Dror Michaelson, Ewa Matczak, et al.
Plos One|August 30, 2019
Treatment sequences for advanced renal cell carcinoma: A health economic assessmentBaris Deniz, Apoorva Ambavane, Shuo Yang, et al.
The New England Journal of Medicine|September 15, 2006
Case records of the Massachusetts General Hospital. Case 28-2006. A 59-year-old man with masses in both kidneysW Scott McDougal, Nina E Tolkoff-Rubin, M Dror Michaelson, et al.
The Journal of Urology|April 20, 2010
Application of a fracture risk algorithm to men treated with androgen deprivation therapy for prostate cancerPhilip J Saylor, Donald S Kaufman, M Dror Michaelson, et al.
Academic Radiology|March 16, 2005
Arterial spin labeling blood flow magnetic resonance imaging for the characterization of metastatic renal cell carcinoma(1)Cedric De Bazelaire, Neil M Rofsky, Guillaume Duhamel, et al.
The New England Journal of Medicine|May 30, 2008
Case records of the Massachusetts General Hospital. Case 17-2008. A 63-year-old man with metastatic renal-cell carcinomaM Dror Michaelson, Othon Iliopoulos, David F McDermott, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|September 18, 2012
Multitargeted tyrosine kinase inhibition produces discordant changes between 99mTc-MDP bone scans and other disease biomarkers: analysis of a phase II study of sunitinib for metastatic castration-resistant prostate cancerPhilip J Saylor, Umar Mahmood, Anchisa Kunawudhi, et al.
Plos One|August 31, 2018
Application of dynamic modeling for survival estimation in advanced renal cell carcinomaBaris Deniz, Arman Altincatal, Apoorva Ambavane, et al.
CA: a Cancer Journal for Clinicians|May 27, 2008
Management of complications of prostate cancer treatmentM Dror Michaelson, Shane E Cotter, Patricio C Gargollo, et al.
Pageof 13